UCB SA (UCB.BR)
EUR 187.45
(0.83%)
EUR 187.45
(0.83%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.56 Billion EUR | -3.53% |
| 2022 | 6.8 Billion EUR | 16.83% |
| 2021 | 5.82 Billion EUR | -3.69% |
| 2020 | 6.04 Billion EUR | 48.5% |
| 2019 | 4.07 Billion EUR | -4.39% |
| 2018 | 4.25 Billion EUR | 1.87% |
| 2017 | 4.18 Billion EUR | -11.7% |
| 2016 | 4.73 Billion EUR | -12.48% |
| 2015 | 5.41 Billion EUR | 2.89% |
| 2014 | 5.25 Billion EUR | -3.29% |
| 2013 | 5.43 Billion EUR | 14.05% |
| 2012 | 4.76 Billion EUR | 9.46% |
| 2011 | 4.35 Billion EUR | -0.5% |
| 2010 | 4.37 Billion EUR | -6.93% |
| 2009 | 4.7 Billion EUR | -14.6% |
| 2008 | 5.5 Billion EUR | 4.08% |
| 2007 | 5.29 Billion EUR | -7.5% |
| 2006 | 5.72 Billion EUR | 147.83% |
| 2005 | 2.3 Billion EUR | -32.29% |
| 2004 | 3.4 Billion EUR | 160.76% |
| 2003 | 1.3 Billion EUR | 23.83% |
| 2002 | 1.05 Billion EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 6.67 Billion EUR | 0.0% |
| 2023 FY | 6.56 Billion EUR | -3.53% |
| 2023 Q2 | 6.34 Billion EUR | 0.0% |
| 2023 Q4 | 6.56 Billion EUR | 0.0% |
| 2022 FY | 6.8 Billion EUR | 16.83% |
| 2022 Q2 | 7.39 Billion EUR | 0.0% |
| 2022 Q4 | 6.8 Billion EUR | 0.0% |
| 2021 Q2 | 5.36 Billion EUR | 0.0% |
| 2021 Q4 | 5.82 Billion EUR | 0.0% |
| 2021 FY | 5.82 Billion EUR | -3.69% |
| 2020 Q4 | 6.04 Billion EUR | 0.0% |
| 2020 Q2 | 6.12 Billion EUR | 0.0% |
| 2020 FY | 6.04 Billion EUR | 48.5% |
| 2019 Q4 | 4.07 Billion EUR | 0.0% |
| 2019 FY | 4.07 Billion EUR | -4.39% |
| 2019 Q2 | 4.06 Billion EUR | 0.0% |
| 2018 Q4 | 4.25 Billion EUR | 0.0% |
| 2018 FY | 4.25 Billion EUR | 1.87% |
| 2018 Q2 | 4.25 Billion EUR | 0.0% |
| 2017 FY | 4.18 Billion EUR | -11.7% |
| 2017 Q2 | 4.27 Billion EUR | 0.0% |
| 2017 Q4 | 4.18 Billion EUR | 0.0% |
| 2016 Q4 | 4.73 Billion EUR | 0.0% |
| 2016 FY | 4.73 Billion EUR | -12.48% |
| 2016 Q2 | 5.12 Billion EUR | 0.0% |
| 2015 Q4 | 5.41 Billion EUR | 0.0% |
| 2015 Q2 | 5.43 Billion EUR | 0.0% |
| 2015 FY | 5.41 Billion EUR | 2.89% |
| 2014 Q2 | 5.06 Billion EUR | 0.0% |
| 2014 FY | 5.25 Billion EUR | -3.29% |
| 2014 Q4 | 5.25 Billion EUR | 0.0% |
| 2013 Q4 | 5.3 Billion EUR | 0.0% |
| 2013 FY | 5.43 Billion EUR | 14.05% |
| 2013 Q2 | 5.06 Billion EUR | 0.0% |
| 2012 Q2 | 4.61 Billion EUR | 0.0% |
| 2012 FY | 4.76 Billion EUR | 9.46% |
| 2012 Q4 | 4.76 Billion EUR | 0.0% |
| 2011 Q4 | 4.35 Billion EUR | 0.0% |
| 2011 Q2 | 3.75 Billion EUR | 0.0% |
| 2011 FY | 4.35 Billion EUR | -0.5% |
| 2010 FY | 4.37 Billion EUR | -6.93% |
| 2010 Q4 | 4.37 Billion EUR | 0.0% |
| 2010 Q2 | 5.26 Billion EUR | 0.0% |
| 2009 Q4 | 4.7 Billion EUR | 0.0% |
| 2009 FY | 4.7 Billion EUR | -14.6% |
| 2008 FY | 5.5 Billion EUR | 4.08% |
| 2007 FY | 5.29 Billion EUR | -7.5% |
| 2006 FY | 5.72 Billion EUR | 147.83% |
| 2005 FY | 2.3 Billion EUR | -32.29% |
| 2004 FY | 3.4 Billion EUR | 160.76% |
| 2003 FY | 1.3 Billion EUR | 23.83% |
| 2002 FY | 1.05 Billion EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -94865.278% |
| ABIVAX Société Anonyme | 131.05 Million EUR | -4908.699% |
| Adocia SA | 31.87 Million EUR | -20496.172% |
| Aelis Farma SA | 13.08 Million EUR | -50083.486% |
| Biophytis S.A. | 15.84 Million EUR | -41315.862% |
| Advicenne S.A. | 24.37 Million EUR | -26827.021% |
| genOway Société anonyme | 14.45 Million EUR | -45295.72% |
| IntegraGen SA | 5.97 Million EUR | -109669.613% |
| Medesis Pharma S.A. | 6.42 Million EUR | -102044.601% |
| Neovacs S.A. | 3.71 Million EUR | -176725.99% |
| NFL Biosciences SA | 3.62 Million EUR | -181191.762% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -96680.586% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -198201.747% |
| Sensorion SA | 13.22 Million EUR | -49524.756% |
| Theranexus Société Anonyme | 5.01 Million EUR | -130756.313% |
| TME Pharma N.V. | 2.78 Million EUR | -235591.203% |
| Valbiotis SA | 13.7 Million EUR | -47784.447% |
| TheraVet SA | 1.48 Million EUR | -441922.286% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -31969.572% |
| argenx SE | 402.79 Million EUR | -1529.6% |
| BioSenic S.A. | 32.26 Million EUR | -20244.657% |
| Celyad Oncology SA | 9.97 Million EUR | -65684.726% |
| DBV Technologies S.A. | 38.74 Million USD | -16841.408% |
| Galapagos NV | 1.56 Billion EUR | -320.276% |
| Genfit S.A. | 105.92 Million EUR | -6097.071% |
| GeNeuro SA | 20.13 Million EUR | -32492.019% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -76119.229% |
| Innate Pharma S.A. | 132.29 Million EUR | -4861.751% |
| Inventiva S.A. | 101.59 Million EUR | -6361.075% |
| MaaT Pharma SA | 22.46 Million EUR | -29118.785% |
| MedinCell S.A. | 77.77 Million EUR | -8340.273% |
| Nanobiotix S.A. | 95.74 Million EUR | -6756.069% |
| Onward Medical N.V. | 25.69 Million EUR | -25442.844% |
| Oryzon Genomics S.A. | 25.12 Million EUR | -26024.857% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | -11010.547% |
| Oxurion NV | 19.73 Million EUR | -33159.019% |
| Pharming Group N.V. | 228.28 Million EUR | -2775.353% |
| Poxel S.A. | 53.9 Million EUR | -12077.882% |
| GenSight Biologics S.A. | 34.72 Million EUR | -18801.719% |
| Transgene SA | 26.51 Million EUR | -24653.931% |
| Financière de Tubize SA | 123.65 Million EUR | -5208.526% |
| Valneva SE | 341.14 Million EUR | -1824.114% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -144258.918% |